Wen Sun

Prof. Wen Sun

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2020 in The Lancet Neurology
Verified
Journal Article
Closed access
XLXinfeng Liu
Xinfeng Liu
QDQiliang Dai
Qiliang Dai
RYRuidong Ye
Ruidong Ye
WZWenjie Zi
Wenjie Zi
YLYuxiu Liu
Yuxiu Liu
RNRaul Nogueira
Raul Nogueira

30 August 2020 in Translational Stroke Research
Verified
Journal Article
Closed access
PDF file
PXPengfei Xu
Pengfei Xu
YHYe Hong
Ye Hong
YXYi Xie
Yi Xie
KYKang Yuan
Kang Yuan
JLJuanji Li
Juanji Li
WSWen Sun
Wen Sun

30 August 2021 in Journal of Neuroinflammation
Verified
Journal Article
Open access
PDF file
PXPengfei Xu
Pengfei Xu
CTChunrong Tao
Chunrong Tao
YZYuyou Zhu
Yuyou Zhu
GWGuoping Wang
Guoping Wang
LKLingqi Kong
Lingqi Kong
WHWei Hu
Wei Hu
Background: Innate immunity can facilitate early brain injury (EBI) following subarachnoid hemorrhage (SAH). Numerous studies suggest that pyroptosis could exacerbate extracellular immune responses by promoting secretion of inflammatory cytokines. Transforming growth factor-β-activated kinase 1 (TAK1) is a quintessential kinase that positively regulates inflammation through NF-κB and MAPK signaling cascades. However, the effects of TAK1 on neuroinflammation in EBI following SAH are largely unknown. Methods: Two hundred and forty-six male C57BL/6J mice were subjected to the endovascular perforation model of SAH. A selective TAK1 inhibitor, 5Z-7-oxozeaenol (OZ) was administered by intracerebroventricular (i.c.v) injection at 30 min after SAH induction. To genetic knockdown of TAK1, small interfering RNA (siRNA) was i.c.v injected at 48 h before SAH induction. SAH grade, brain water content, BBB permeability, neurological score, western blot, real-time PCR, ELISA, transmission electron microscope, and immunofluorescence staining were performed. Long-term behavioral sequelae were evaluated by the rotarod and Morris water maze tests. Furthermore, OZ was added to the culture medium with oxyhemoglobin (OxyHb) to mimic SAH in vitro. The reactive oxygen species level was detected by DCFH-DA staining. Lysosomal integrity was assessed by Lyso-Tracker Red staining and Acridine Orange staining. Results: The neuronal phosphorylated TAK1 expression was upregulated following SAH. Pharmacologic inhibition of TAK1 with OZ could alleviate neurological deficits, brain edema, and brain-blood barrier (BBB) disruption at 24 h after SAH. In addition, OZ administration restored long-term neurobehavioral function. Furthermore, blockade of TAK1 dampened neuronal pyroptosis by downregulating the N-terminal fragment of GSDMD (GSDMD-N) expression and IL-1β/IL-18 production. Mechanistically, both in vivo and in vitro, we demonstrated that TAK1 can induce neuronal pyroptosis through promoting nuclear translocation of NF-κB p65 and activating nucleotide-binding oligomerization domain (NOD)-like receptor pyrin domain containing 3 (NLRP3) inflammasome. TAK1 siRNA treatment mitigated SAH-induced neurobehavioral deficits and restrained phosphorylated NF-κB p65 expression and NLRP3 inflammasome activation. TAK1 blockade also ameliorated reactive oxygen species (ROS) production and prevented lysosomal cathepsin B releasing into the cytoplasm. Conclusions: Our findings demonstrate that TAK1 modulates NLRP3-mediated neuronal pyroptosis in EBI following SAH. Inhibition of TAK1 may serve as a potential candidate to relieve neuroinflammatory responses triggered by SAH.

1 May 2021 in Clinical Nutrition
Verified
Journal Article
Closed access
KYKang Yuan
Kang Yuan
SZShuanggen Zhu
Shuanggen Zhu
HWHuaiming Wang
Huaiming Wang
JCJingjing Chen
Jingjing Chen
XZXiaohao Zhang
Xiaohao Zhang
XLXinfeng Liu
Xinfeng Liu

22 February 2022 in International Journal of Stroke
Verified
Journal Article
Closed access
CTChunrong Tao
Chunrong Tao
RLRui Li
Rui Li
YZYuyou Zhu
Yuyou Zhu
SQSen Qun
Sen Qun
PXPengfei Xu
Pengfei Xu
WHWei Hu
Wei Hu
Background and hypothesis: Recently, two multicenter randomized controlled trials (RCT) failed to show a significantly beneficial effect of endovascular treatment (EVT) in patients with acute basilar artery occlusion (BAO). However, both trials suffered from equipoise issues which may have hindered the validity of the trial results. Therefore, additional RCT studies are needed to explore the potential benefit of EVT in patients presenting with BAO. Study design: ATTENTION is an investigator-initiated, multicenter, prospective, randomized, controlled clinical trial with open-label treatment and blinded outcome assessment (PROBE) of EVT versus best medical management (BMM). The primary effect parameter is a modified Rankin Score of 0–3 at day 90. Discussion: ATTENTION will provide evidence for the efficacy and safety of EVT in stroke patients within 12 h after BAO. Trial registration: ClinicalTrials.gov NCT04751708

1 August 2023 in Journal of Inflammation Research
Verified
Journal Article
Open access
PDF file
PGPengxin Ge
Pengxin Ge
HDHuijie Duan
Huijie Duan
CTChunrong Tao
Chunrong Tao
SNSensen Niu
Sensen Niu
YHYiran Hu
Yiran Hu
WSWen Sun
Wen Sun
Objective: Stroke is a kind of cerebrovascular disease with high mortality. TMAO has been shown to aggravate stroke outcomes, but its mechanism remains unclear. Materials and Methods: Mice were fed with 0.12% TMAO for 16 weeks. Then, mice were made into MCAO/R models. Neurological score, infarct volume, neuronal damage and markers associated with inflammation were assessed. Since microglia played a crucial role in ischemic stroke, microglia of MCAO/R mice were isolated for high-throughput sequencing to identify the most differentially expressed gene following TMAO treatment. Afterward, the downstream pathways of TMAO were investigated using primary microglia. Results: TMAO promoted the release of inflammatory cytokines in the brain of MCAO/R mice and promoted the activation of OGD/R microglial inflammasome, thereby exacerbating ischemic stroke outcomes. FTO/IGF2BP2 inhibited NLRP3 inflammasome activation in OGD/R microglia by downregulating the m6A level of NLRP3. TMAO can inhibit the expression of FTO and IGF2BP2, thus promoting the activation of NLRP3 inflammasome in OGD/R microglia. In conclusion, these results demonstrated that TMAO promotes NLRP3 inflammasome activation of microglia aggravating neurological injury in ischemic stroke through FTO/IGF2BP2. Conclusion: Our results demonstrated that TMAO promotes NLRP3 inflammasome activation of microglia aggravating neurological injury in ischemic stroke through FTO/IGF2BP2. These findings explained the molecular mechanism of TMAO aggravating ischemic stroke in detail and provided molecular mechanism for clinical treatment.